Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre

Australas J Dermatol. 2021 Aug;62(3):e431-e432. doi: 10.1111/ajd.13632. Epub 2021 May 27.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adalimumab / therapeutic use*
  • Adolescent
  • Adult
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Drug Substitution*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Tertiary Care Centers*
  • Treatment Outcome
  • Tumor Necrosis Factor Inhibitors / therapeutic use*
  • Young Adult

Substances

  • Biosimilar Pharmaceuticals
  • Tumor Necrosis Factor Inhibitors
  • Adalimumab